FDA clears Boston Scientific to resume some defib distribution
April 16, 2010 by MassDevice staff
The Food & Drug Administration clears recent manufacturing changes made by by Boston Scientific Corp., partially resolving a notification glitch that had idled company's top-selling defibrillator implants for the past month.
Boston Scientific Corp. (NYSE:BSX) resumed U.S. shipments of its Cognis and Teligen defibrillators after federal regulators cleared recent changes to the company's manufacturing processes.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- FDA Issues Draft Guidance to Help Companies Distinguish Between a Voluntary Medical Device Recall and a Product Enhancement
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
Navigation
NEWS
FDA panel to consider down-classifying blade-form dental implants
The FDA's Dental Products Panel is scheduled to deliberate on whether the agency should lower blade-...
EuroPCR: New data showing reduced mortality in InspireMD's MGuard stent trial
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios recalls GoPump and GOBlock kits following patient complaints
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien launches its new respiratory monitoring device
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
New Xbox One Kinect game system can measure heartbeat visually | MassDevice.com On Call
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
